Drug Pipeline

EYP-1901 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
4
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-04 NCT07449936
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901…		 Trial sites expanded: 46 -> 65 locations
2026-06-04 NCT07449923
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901…		 Trial sites expanded: 48 -> 62 locations
Active Studies by Phase
Phase 3
4
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07449923 CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901… Diabetic Macular Edema Recruiting
NCT07449936 COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901… Diabetic Macular Edema Recruiting
NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)… Wet Age Related Macular Degeneration Active, Not Recruiting
NCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)… Wet Age Related Macular Degeneration Active, Not Recruiting
Sponsors Running EYP-1901 Trials
EyePoint Pharmaceuticals, Inc. (4)
Get alerts when EYP-1901 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free